Actually, that is what the drug (MTX-463) is supposed to treat, via the WISP-1 pathway, through CCN4 gene receptors. It just seems like another checkpoint inhibitor. I think Leronlimab will do similar treatment via VCAM-1 down regulation through the down regulation of TNF-a and IL-1. Additionally, down regulation of PKC, PKR, and MAPK should help. In other words, I think Leronlimab might be an effective treatment, for what this drug is targeting. However, Ohm20 is far more adept at figuring this out, than I am. Today, I have been dealing with snow, power outage, and keeping the fireplace going. So, I haven't been able to spend much time on it.